ArticleExperimental and clinical psychopharmacology2025
Physiological and subjective effects of an oral nicotine pouch in people who use smokeless tobacco.
Article in Experimental and clinical psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Nicotine pouches (NPs) contain no tobacco leaf but instead are filled with nicotine powder, flavorants, and pH adjusters. There are very few independent (i.e., non-industry-funded/affiliated) studies regarding the effects of NPs. The purpose of this industry-independent study is to examine NP effects in people who use smokeless tobacco (SLT). Twenty-four participants completed four sessions that included three NP conditions (2, 4, and 8 mg labeled total nicotine content; "on!" brand, Altria, Richmond, Virginia) and participants' own brand (OB) SLT. Participants completed two 30-min administration periods per session, and outcomes included plasma nicotine concentration as well as subjective and behavioral economic measures. Results indicate that the 8 mg NP did not differ significantly from OB across physiological and subjective measures; the 4 mg NP differed from OB and 8 mg on some measures, and the 2 mg NP reliably delivered less nicotine and reduced abstinence symptoms less effectively when compared to OB and the 8 mg NP. Study results offer preliminary support for the notion that higher nicotine content NPs may substitute for SLT in people who use SLT regularly, while lower nicotine content NPs may not. Overall, labeled nicotine content influences the nicotine delivery and abstinence symptom suppression of "on!" brand NP, and nicotine content and delivery should be considered when assessing the individual and public health impact of NP regulations. (PsycInfo Database Record (c) 2025 APA, all rights reserved).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.